Elevai Labs, Inc. (ELAB)
| Market Cap | 48.70M |
| Revenue (ttm) | 1.03M |
| Net Income (ttm) | -3.51M |
| Shares Out | 17.33M |
| EPS (ttm) | -0.20 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 333,283 |
| Open | 3.31 |
| Previous Close | 3.55 |
| Day's Range | 2.41 - 3.63 |
| 52-Week Range | 2.41 - 4.24 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Dec 14, 2023 |
About ELAB
Elevai Labs is a physician-dispensed skincare company with a focus on modernizing aesthetic skincare. We conduct research and development to advance innovative and science-driven topical skincare that complements the medical aesthetics industry. Upon our founding in 2020, we initiated our research and development phase for our current product formulations. Since 2022, we have principally employed a business-to-business model in which we produce and commercialize a new generation of topical skincare products that contain our proprietary stem cel... [Read more]
Financial Performance
Financial StatementsNews
Elevai Labs Enters into Licensing Agreement with Yuva Biosciences to Combine Exosome and Mitochondrial Technologies to Develop New Aesthetics Products
NEWPORT BEACH, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (Nasdaq: ELAB) a medical aesthetic company specializing in physician-dispensed skincare, today announced that they have signe...
Elevai Labs IPO Registration Document (S-1)
Elevai Labs has filed to go public with an IPO on the NASDAQ.